Evaluation of Renal Adverse Effects of Combination Anti-retroviral Therapy including Tenofovir in HIV-infected Patients

Evaluation of Renal Adverse Effects of Combination Anti-retroviral Therapy including Tenofovir in HIV-infected Patients

Purpose. In order to maintain plasma HIV-RNA concentration in HIV-infected patients, below the detection limit combination anti-retroviral therapy (cART) are used. Although the nucleoside/nucleotide reverse transcriptase inhibitor, tenofovir disoproxil fumarate (TDF) is a first-line drug commonly us...

Full description

Bibliographic Details
Main Authors:	Hiroyuki Tanaka, Mariko Arai, Yoshinori Tomoda, Tatsuhiko Wada, Kazuo Yago, Mitsutoshi Satoh
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2013-05-01
Series:	Journal of Pharmacy & Pharmaceutical Sciences
Online Access:	https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/18802

Similar Items

Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients
by: Junyang Yang, et al.
Published: (2019-06-01)

Evaluation of the Efficacy and Safety of Changes in Antiretroviral Regimens for HIV-infected Patients
by: Hiroyuki Tanaka, et al.
Published: (2014-07-01)

An overview of tenofovir and renal disease for the HIV-treating clinician
by: Willem D.F. Venter, et al.
Published: (2018-07-01)

Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya.
by: Mercy Jelagat Karoney, et al.
Published: (2022-01-01)

Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya
by: Mercy Jelagat Karoney, et al.
Published: (2022-01-01)

Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV
by: Milena M McLaughlin, et al.
Published: (2018-03-01)

Analysis of patients with hypomagnesemia using the Japanese Adverse Drug Event Report database (JADER)
by: Hiroyuki Tanaka, et al.
Published: (2018-03-01)

Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir
by: Daniel Yilma, et al.
Published: (2020-08-01)

Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana
by: Edmund T. Nartey, et al.
Published: (2019-07-01)

Associations between plasma tenofovir concentration and renal function markers in HIV-infected women
by: Mwila Mulubwa, et al.
Published: (2016-07-01)

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial
by: Zhao, Y, et al.
Published: (2021)

Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection
by: Defu Yuan, et al.
Published: (2023-03-01)

Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors
by: Pontrelli Giuseppe, et al.
Published: (2012-01-01)

Fanconi syndrome induced by tenofovir in HIV patients
by: Mounira Rai, et al.
Published: (2018-05-01)

Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue
by: Laura Else, et al.
Published: (2022-06-01)

Renal Concerns in the Treatment of Chronic Hepatitis B with Tenofovir
by: Giuseppe Coppolino, et al.
Published: (2017-03-01)

Risk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate
by: Angsana Phuphuakrat MD, PhD, et al.
Published: (2022-10-01)

Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.
by: Junko Tanuma, et al.
Published: (2016-01-01)

Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report
by: Jack E. Heron, et al.
Published: (2020-08-01)

Analysis of the Time-To-Onset and Factors Affecting Clinical Outcomes of Immune Reconstitution Inflammatory Syndrome in People Living with HIV Using Data from the Japanese Spontaneous Reporting Database
by: Hiroyuki Tanaka, et al.
Published: (2021-04-01)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
by: Yang YM, et al.
Published: (2017-09-01)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
by: Chanie Wassner PharmD, BCCCP, BCIDP, et al.
Published: (2020-04-01)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
by: Inès Devred, et al.
Published: (2023-09-01)

Acute retroviral syndrome in Slovenian patients infected with HIV
by: Mateja Pirš, et al.
Published: (2005-06-01)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
by: Aida N. Kawuma, et al.
Published: (2023-06-01)

Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.
by: Takeshi Nishijima, et al.
Published: (2012-01-01)

Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study.
by: Jack E Heron, et al.
Published: (2023-01-01)

Longitudinal Progression of Estimated GFR in HIV-1-Infected Patients with Normal Renal Function on Tenofovir-Based Therapy in China
by: Liu F, et al.
Published: (2020-04-01)

Proximal renal tubular function in HIV-infected children on tenofovir disoproxil fumarate for treatment of HIV infection at two tertiary hospitals in Harare, Zimbabwe.
by: Runyararo Mashingaidze-Mano, et al.
Published: (2020-01-01)

Effect of tenofovir on nucleotidases and cytokines in HIV-1 target cells.
by: Nabanita Biswas, et al.
Published: (2013-01-01)

Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.
by: Thanyanan Chaowanachan, et al.
Published: (2013-01-01)

Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV
by: Ashana Puri, et al.
Published: (2019-04-01)

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
by: Andrea Ries Thurman, et al.
Published: (2019-01-01)

The Effect of Tenofovir Treatment on Renal Function in Chronic Hepatitis B Patients
by: Yusuf Kayar, et al.
Published: (2019-10-01)

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
by: Tomoya Sano, et al.
Published: (2021-03-01)

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
by: Chua Arlene C, et al.
Published: (2012-06-01)

Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir.
by: Theys, K, et al.
Published: (2013)

The moral and fiscal implications of anti-retroviral therapies for HIV in Africa
by: Sterck, O, et al.
Published: (2015)

Balance between Retroviral Latency and Transcription: Based on HIV Model
by: Aneta Pluta, et al.
Published: (2020-12-01)

Tooth wear in patients treated with HIV anti-retroviral therapy
by: Harjit Singh Sehgal, et al.
Published: (2019-06-01)